A novel platinum(II) complex bearing 6,6′-Bis(N-Methylbenzimidazol-2-yl)-2,2′-bipyridine: Synthesis, characterization, and anticancer activity

Yilmaz I., BOSTANCI H. E.

Journal of Molecular Structure, cilt.1366, 2026 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1366
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.molstruc.2026.146078
  • Dergi Adı: Journal of Molecular Structure
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, Chimica, Compendex, INSPEC
  • Anahtar Kelimeler: 2,2′-bipyridine, Anticancer, Benzimidazole, N4-donor ligand, Platinum(II) complex
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

A new mononuclear cationic platinum(II) coordination compound [Pt(L)]-Cl2 (1) with 6,6′-bis(N-Methylbenzimidazol-2-yl)-2,2′-bipyridine (L) ligand having N4-tetradentate binding pocket was synthesized and characterized by FT-IR, 1HNMR, ESI-MS, MALDI TOF-MS, and CHN analysis. The ligand (L) structure is also determined by single-crystal X-ray diffraction. The anticancer properties of complex 1 were investigated. The complex 1 was evaluated for its in vitro cytotoxic potential against L929 (healthy fibroblast), A549 (lung carcinoma), MCF7 (breast adenocarcinoma), and MDA (breast carcinoma) cell lines using the MTT assay after 24 h of exposure. The obtained IC₅₀ values were 41.85 ± 3.59 µM (L929), 39.79 ± 1.52 µM (A549), 33.60 ± 10.77 µM (MCF7), and 32.88 ± 0.48 µM (MDA). Compared with cisplatin, complex 1 displayed moderate yet consistent cytotoxicity across cancer cell lines and partial selectivity over healthy fibroblasts. The data suggest that complex 1 may represent a balanced lead structure, exhibiting measurable anticancer activity while maintaining limited toxicity, which warrants further investigation into its mechanistic properties.